Women's Health Devices cybersecurity.

• Cycle-tracking and fertility apps with sensor input
• At-home fertility and ovulation hardware
• Connected breast pumps with telemetry
• Pelvic-floor therapeutics and biofeedback devices
• Maternal RPM and postpartum monitoring

• Device ↔ phone (BLE, authenticated pairing)
• App ↔ cloud back-end (TLS, OAuth)
• Cloud ↔ clinician portal / EHR (FHIR)
• App ↔ third-party SDKs (analytics, ads - inventoried and controlled)
• Cloud ↔ partner / payer integrations (scoped APIs)

How do you handle reproductive-data sensitivity in a threat model?

Reproductive, menstrual, and fertility data is high-sensitivity health information that can carry legal exposure beyond HIPAA - particularly under state-level reproductive privacy statutes. We model misuse and over-collection alongside conventional confidentiality, integrity, and availability threats, and we recommend explicit retention windows, minimization, and access patterns FDA reviewers and privacy counsel both expect to see. The SPDF documents the data classification, lawful basis, and the controls (encryption, access scoping, audit) that enforce it.

What's the playbook for consumer-grade hardware becoming a cleared device?

Consumer hardware moving into a regulated indication usually carries baseline hygiene problems - default credentials, exposed debug interfaces (UART/JTAG/SWD), insecure radios, undocumented OTA paths, and unsigned firmware. We run a hardening sweep first, lock down those baseline issues, generate a clean SBOM, and only then build the FDA-aligned premarket cyber package on top. Trying to add the FDA package without remediating the consumer-era debt almost always produces deficiency letters.

Do connected fetal/maternal monitors get the full premarket cyber package?

Yes. Connected fetal and maternal monitors are networked medical devices with safety-relevant alarms - exactly the class of product the 2026 FDA premarket cyber guidance and AAMI SW96 are written for. Deliverables include the threat model, SBOM (SPDX or CycloneDX) with VEX, security architecture views, authenticated penetration testing of device, app, and cloud, MDS2, labeling content, and a postmarket cybersecurity management plan under section 524B.

How do you cover partner / caregiver sharing in fertility and pregnancy apps?

Account sharing is modeled as an explicit authorization boundary with explicit consent and revocation flows, not as a UI feature. The API is tested for BOLA (broken object-level authorization), tenancy leaks across linked accounts, and stale-token access after revocation - these are the most common findings in this segment. The threat model and the privacy policy must agree on what a 'partner' can see and for how long; if they don't, the inconsistency surfaces in both FDA review and state AG inquiries.

Is HIPAA enough for a women's health platform?

No. HIPAA covers a slice (covered entities, business associates, breach response) and applies only when the platform is acting in those roles. FDA premarket cybersecurity content is required when the product is a regulated device, regardless of HIPAA status. State-level reproductive privacy laws (e.g., Washington's MHMDA, California, Connecticut) impose additional obligations on consent, sale, and disclosure of reproductive health data and need to be reflected in the security and privacy design.

How do you document cloud regions and data residency?

The SPDF and the privacy notice should tell the same story: storage regions, key custody, replication scope, sub-processor list, and any cross-border transfer mechanisms. We document the data flows in the threat model, identify any data that leaves the primary region (including incidentally - logs, metrics, support tooling), and verify the controls in pen testing. This single coherent story is what reviewers, hospital procurement, and privacy counsel all need.

What about cycle-tracking algorithms that influence clinical decisions?

When predictions affect clinical decisions (e.g., fertility windows used for conception or contraception), the algorithm is part of the regulated software and the cyber package must address its supply chain, model integrity, training data lineage, and adversarial-input resistance. We treat it the same way we treat AI/SaMD: signing, version pinning, load-time verification, and PCCP-aware change control.

How do you handle pregnancy and pediatric data retention?

Pregnancy data carries an extra duty because it implicates the fetus and, after birth, a separate pediatric record. We document retention separately for the gestational period, postpartum, and pediatric continuation, with explicit deletion paths and parental consent flows. These controls are tested in the cloud pen test and called out in the labeling and IFU.

Do you cover wearables that pair with women's health apps?

Yes. Paired wearables (BLE thermometers, smart rings, breast pumps, pelvic-floor trainers) are scoped as part of the system: BLE pairing mode, OTA signing, sensor-spoofing resistance, and battery/DoS handling are all in the test plan. Findings against the wearable feed back into the device-level threat model and SBOM.

What's the postmarket plan look like for women's health software?

Continuous SBOM monitoring across mobile, web, backend, and any wearable firmware; a published Coordinated Vulnerability Disclosure (CVD) intake; defined SLAs by severity; and a documented path from CVE to controlled software change under your QMS. Because this segment frequently ships fast through app stores, the postmarket plan must explicitly address how mobile updates are managed without breaking the cleared interoperability or claims.

How long does a women's-health premarket cyber engagement take?

Typical end-to-end timeline is 4-8 weeks for a software-only DTx-style product and 8-12 weeks when paired wearables, fetal/maternal monitors, or significant cloud architecture are in scope. Threat modeling and SBOM front-load in weeks 1-3, mobile/web/API and (where applicable) device pen testing run in weeks 3-8, and the consolidated submission package and postmarket plan close out in the final weeks. Scope and clearance-guarantee terms are confirmed in writing before kickoff.